AI drug discovery company

GALUX

Data as of Oct 17, 2026.

Company facts

Founded

2020

ReportedSource for founded (opens in new tab)
Headquarters

South Korea (Seoul)

ConfirmedSource for headquarters (opens in new tab)
Total funding

$47M

ConfirmedSource for total funding (opens in new tab)

Latest funding round

Round: Series B
Date: Feb 9, 2026
Amount: $29M
Lead investor: Yuanta Investment

ConfirmedSource for the latest round (opens in new tab)

Drug discovery partners

1 pharma. Pharma here means a company with approved products and roughly $1B or more in annual revenue.

Boehringer Ingelheim Pharma

Protein design agreement, Dec 23, 2025

Terms not disclosed

ReportedSource for Boehringer Ingelheim (opens in new tab)

Recent news

Feb 9, 2026

Series B: $29M

ConfirmedSource (opens in new tab)
Dec 23, 2025

Agrees with Boehringer Ingelheim to design purpose-specific protein molecules

ReportedSource (opens in new tab)
Nov 26, 2025

Reports high-affinity de novo antibodies from only 50 AI designs

ConfirmedSource (opens in new tab)

Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.

Spot an error? Tell me and I'll fix it.